Investigational Drug Details
| Drug ID: | D370 |
| Drug Name: | Tirzepatide |
| Synonyms: | Tirzepatide |
| Type: | Biological drug |
| DrugBank ID: | DB15171 |
| DrugBank Description: | Tirzepatide is under investigation in clinical trial NCT03311724 (A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes). |
| PubChem ID: | -- |
| CasNo: | 2023788-19-2 |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | GIP agonist; GLP-1 receptor agonist |
| Therapeutic Category: | Improve insulin resistance |
| Clinical Trial Progress: | Phase 3 completed (In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0195 | NCT04166773 | Phase 2 | Recruiting | No Results Available | November 19, 2019 | March 10, 2022 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A06147 | 32987188 | Mol Metab | Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. | Details |
| A07979 | 32291277 | Diabetes Care | Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. | Details |
| A47679 | 33778934 | Clin Pharmacokinet | Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. | Details |
| A47719 | 33030356 | Expert Rev Endocrinol Metab | Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. | Details |
| A47735 | 32730231 | JCI Insight | Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. | Details |
| A49279 | 35803320 | Metabolism | Recent guidelines for non-alcoholic fatty liver disease (NAFLD): Are they already outdated and in need of supplementation? | Details |
| A51317 | 35674880 | Clin Pharmacokinet | Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. | Details |
| A51396 | 35830001 | Drugs | Tirzepatide: First Approval. | Details |